Correspondence to editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients"

. 2024 Oct;30(4):994-996.

doi: 10.3350/cmh.2024.0552. Epub 2024 Jul 23.

Xiaoqian Xu^{1

2}, Hong You³, Jidong Jia³, Yuanyuan Kong^{1

2}

Affiliations

¹ National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
² Clinical Epidemiology and EBM Unit, Beijing Clinical Research Institute, Beijing, China.
³ Liver Research Center, Beijing Friendship Hospital, Capital Medical University; State Key Lab of Digestive Health, Beijing, China.

Xiaoqian Xu et al. Clin Mol Hepatol. 2024 Oct.

. 2024 Oct;30(4):994-996.

doi: 10.3350/cmh.2024.0552. Epub 2024 Jul 23.

Xiaoqian Xu^{1

2}, Hong You³, Jidong Jia³, Yuanyuan Kong^{1

2}

¹ National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
² Clinical Epidemiology and EBM Unit, Beijing Clinical Research Institute, Beijing, China.
³ Liver Research Center, Beijing Friendship Hospital, Capital Medical University; State Key Lab of Digestive Health, Beijing, China.

No abstract available

Keywords: Antiviral therapy; CHB; HCC prediction.

Conflict of interest statement

Conflicts of Interest

The authors declare no conflicts of interest for this work.

Prediction Model for Familial Aggregated HBV-Associated Hepatocellular Carcinoma Based on Serum Biomarkers.
Zhong L, Nie G, Wu Q, Zhang H, Wang H, Yan J. Zhong L, et al. Cancer Rep (Hoboken). 2025 Jun;8(6):e70253. doi: 10.1002/cnr2.70253. Cancer Rep (Hoboken). 2025. PMID: 40551431 Free PMC article.
Reply to correspondence on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".
Kim BK. Kim BK. Clin Mol Hepatol. 2024 Oct;30(4):1044-1046. doi: 10.3350/cmh.2024.0584. Epub 2024 Jul 29. Clin Mol Hepatol. 2024. PMID: 39069724 Free PMC article. No abstract available.

1. Kim BK. Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with longterm antiviral therapy in chronic hepatitis B patients”. Clin Mol Hepatol. 2024;30:656–658. - PMC - PubMed
1. Wu X, Xu X, Zhou J, Sun Y, Ding H, Xie W, et al. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients. Clin Mol Hepatol. 2023;29:747–762. - PMC - PubMed
1. Wen X, Wu X, Sun Y, Zhou J, Guan G, Chen S, et al. Longterm antiviral therapy is associated with changes in the profile of transcriptionally active HBV integration in the livers of patients with CHB. J Med Virol. 2024;96:e29606. - PubMed
1. Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol. 2022;19:727–745. - PMC - PubMed
1. Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, et al. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol. 2022;76:311–318. - PubMed